FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2109756862> ?p ?o ?g. }

• W2109756862 abstract "Hypoxic-ischaemic encephalopathy is associated with development of cerebral palsy and cognitive disability later in life and is therefore one of the fundamental problems in perinatal medicine. The xanthine-oxidase inhibitor allopurinol reduces the formation of free radicals, thereby limiting the amount of hypoxia-reperfusion damage. In case of suspected intra-uterine hypoxia, both animal and human studies suggest that maternal administration of allopurinol immediately prior to delivery reduces hypoxic-ischaemic encephalopathy. The proposed trial is a randomized double blind placebo controlled multicenter study in pregnant women at term in whom the foetus is suspected of intra-uterine hypoxia. Allopurinol 500 mg IV or placebo will be administered antenatally to the pregnant woman when foetal hypoxia is suspected. Foetal distress is being diagnosed by the clinician as an abnormal or non-reassuring foetal heart rate trace, preferably accompanied by either significant ST-wave abnormalities (as detected by the STAN-monitor) or an abnormal foetal blood scalp sampling (pH < 7.20). Primary outcome measures are the amount of S100B (a marker for brain tissue damage) and the severity of oxidative stress (measured by isoprostane, neuroprostane, non protein bound iron and hypoxanthine), both measured in umbilical cord blood. Secondary outcome measures are neonatal mortality, serious composite neonatal morbidity and long-term neurological outcome. Furthermore pharmacokinetics and pharmacodynamics will be investigated. We expect an inclusion of 220 patients (110 per group) to be feasible in an inclusion period of two years. Given a suspected mean value of S100B of 1.05 ug/L (SD 0.37 ug/L) in the placebo group this trial has a power of 90% (alpha 0.05) to detect a mean value of S100B of 0.89 ug/L (SD 0.37 ug/L) in the 'allopurinol-treated' group (z-test2-sided). Analysis will be by intention to treat and it allows for one interim analysis. In this trial we aim to answer the question whether antenatal allopurinol administration reduces hypoxic-ischaemic encephalopathy in neonates exposed to foetal hypoxia. Clinical Trials, protocol registration system: NCT00189007" @default.
• W2109756862 created "2016-06-24" @default.
• W2109756862 creator A5008998287 @default.
• W2109756862 creator A5016922338 @default.
• W2109756862 creator A5018111738 @default.
• W2109756862 creator A5026450012 @default.
• W2109756862 creator A5030066936 @default.
• W2109756862 creator A5031572840 @default.
• W2109756862 creator A5031740471 @default.
• W2109756862 creator A5038316431 @default.
• W2109756862 creator A5048253815 @default.
• W2109756862 creator A5049062183 @default.
• W2109756862 creator A5051496088 @default.
• W2109756862 creator A5052933621 @default.
• W2109756862 creator A5062946839 @default.
• W2109756862 creator A5063991266 @default.
• W2109756862 creator A5064803155 @default.
• W2109756862 creator A5066957546 @default.
• W2109756862 creator A5067211712 @default.
• W2109756862 creator A5068423339 @default.
• W2109756862 creator A5070717459 @default.
• W2109756862 creator A5077559727 @default.
• W2109756862 creator A5077851692 @default.
• W2109756862 creator A5078176492 @default.
• W2109756862 creator A5079022884 @default.
• W2109756862 creator A5084538654 @default.
• W2109756862 creator A5086871511 @default.
• W2109756862 creator A5090045839 @default.
• W2109756862 creator A5090795384 @default.
• W2109756862 creator A5090875096 @default.
• W2109756862 creator A5091610751 @default.
• W2109756862 date "2010-02-18" @default.
• W2109756862 modified "2023-10-14" @default.
• W2109756862 title "Antenatal allopurinol for reduction of birth asphyxia induced brain damage (ALLO-Trial); a randomized double blind placebo controlled multicenter study" @default.
• W2109756862 cites W1992659712 @default.
• W2109756862 cites W2002269747 @default.
• W2109756862 cites W2011864367 @default.
• W2109756862 cites W2013083184 @default.
• W2109756862 cites W2016619395 @default.
• W2109756862 cites W2019381469 @default.
• W2109756862 cites W2022091875 @default.
• W2109756862 cites W2030797281 @default.
• W2109756862 cites W2035125822 @default.
• W2109756862 cites W2041129027 @default.
• W2109756862 cites W2060064603 @default.
• W2109756862 cites W2066215889 @default.
• W2109756862 cites W2090673332 @default.
• W2109756862 cites W2099500782 @default.
• W2109756862 cites W2107635097 @default.
• W2109756862 cites W2109521624 @default.
• W2109756862 cites W2115863844 @default.
• W2109756862 cites W2135122869 @default.
• W2109756862 cites W2146710394 @default.
• W2109756862 cites W2156525348 @default.
• W2109756862 doi "https://doi.org/10.1186/1471-2393-10-8" @default.
• W2109756862 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2834613" @default.
• W2109756862 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20167117" @default.
• W2109756862 hasPublicationYear "2010" @default.
• W2109756862 type Work @default.
• W2109756862 sameAs 2109756862 @default.
• W2109756862 citedByCount "63" @default.
• W2109756862 countsByYear W21097568622012 @default.
• W2109756862 countsByYear W21097568622013 @default.
• W2109756862 countsByYear W21097568622014 @default.
• W2109756862 countsByYear W21097568622015 @default.
• W2109756862 countsByYear W21097568622016 @default.
• W2109756862 countsByYear W21097568622017 @default.
• W2109756862 countsByYear W21097568622018 @default.
• W2109756862 countsByYear W21097568622019 @default.
• W2109756862 countsByYear W21097568622020 @default.
• W2109756862 countsByYear W21097568622021 @default.
• W2109756862 countsByYear W21097568622022 @default.
• W2109756862 crossrefType "journal-article" @default.
• W2109756862 hasAuthorship W2109756862A5008998287 @default.
• W2109756862 hasAuthorship W2109756862A5016922338 @default.
• W2109756862 hasAuthorship W2109756862A5018111738 @default.
• W2109756862 hasAuthorship W2109756862A5026450012 @default.
• W2109756862 hasAuthorship W2109756862A5030066936 @default.
• W2109756862 hasAuthorship W2109756862A5031572840 @default.
• W2109756862 hasAuthorship W2109756862A5031740471 @default.
• W2109756862 hasAuthorship W2109756862A5038316431 @default.
• W2109756862 hasAuthorship W2109756862A5048253815 @default.
• W2109756862 hasAuthorship W2109756862A5049062183 @default.
• W2109756862 hasAuthorship W2109756862A5051496088 @default.
• W2109756862 hasAuthorship W2109756862A5052933621 @default.
• W2109756862 hasAuthorship W2109756862A5062946839 @default.
• W2109756862 hasAuthorship W2109756862A5063991266 @default.
• W2109756862 hasAuthorship W2109756862A5064803155 @default.
• W2109756862 hasAuthorship W2109756862A5066957546 @default.
• W2109756862 hasAuthorship W2109756862A5067211712 @default.
• W2109756862 hasAuthorship W2109756862A5068423339 @default.
• W2109756862 hasAuthorship W2109756862A5070717459 @default.
• W2109756862 hasAuthorship W2109756862A5077559727 @default.
• W2109756862 hasAuthorship W2109756862A5077851692 @default.
• W2109756862 hasAuthorship W2109756862A5078176492 @default.
• W2109756862 hasAuthorship W2109756862A5079022884 @default.
• W2109756862 hasAuthorship W2109756862A5084538654 @default.
• W2109756862 hasAuthorship W2109756862A5086871511 @default.
• W2109756862 hasAuthorship W2109756862A5090045839 @default.
• W2109756862 hasAuthorship W2109756862A5090795384 @default.

• next